• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»GTB-5550

Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors

By Soujanya Ravi on February 3, 2026   Pharma & Biotech  

Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors

GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.

GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation

By Soujanya Ravi on January 16, 2026   Pharma & Biotech  

GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation

Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.

Recent Posts

  • Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?
  • Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?
  • Medtronic backs Pulnovo Medical in $100m round to expand PADN in pulmonary hypertension
  • Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update
  • Orthogon Therapeutics adds $11m for BK virus drug, targeting one of transplant medicine’s toughest gaps
  • LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?
  • Obodence at WCO 2026: Samsung Bioepis sharpens the clinical case for SB16 adoption
  • Khondrion moves sonlicromanol into Phase 3, but can KHENERFIN finally crack mitochondrial disease?
  • Why Bruker’s ESCMID 2026 microbiology expansion could matter for hospital labs and infection control
  • Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?
  • Drug Farm’s DF-003 shows early signal in ROSAH syndrome, but can ALPK1 inhibition hold up in pivotal testing?
  • Why MyGenius PRO could strengthen Bruker’s position in automated infectious disease diagnostics
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes